Posts

AstraZeneca’s pipeline struggles continue with disappointing late-stage cancer and rare disease data

on

BeOne boosts US footprint with $300M New Jersey expansion

on

BMS expands AI footprint with Nvidia, aiming for most powerful AI factory in life sciences

on

Post-Hoc Live: What's making biotech IPOs work again?

on

Novartis to Acquire UK Biotech Myricx Bio for Up to $1.5 Billion to Expand ADC Oncology Pipeline

on

FDA Approvals Outrun Staff Cuts: 23 Novel Drugs Mark Best First Half in Three Years

on

Ipsen signals more deals to continue buying spree

on

Lilly offers up to $1.9B in new drug discovery deal with Abbisko

on

Pfizer'

on

GSK to Acquire Nuvalent for $10.6 Billion, Marking Its Largest Oncology Push in a Decade

on

Treeline to go public via reverse merger with Standard BioTools

on

AstraZeneca CEO says AI is reshaping drug development and helping boost the odds of success

on

ChatGPT and other LLMs for cancer patient education: help or hindrance?

on

Akeso takes center stage at ASCO 2026 as China biotech cements its global arrival

on

Lilly bets $3B+ to add China's Haisco to growing list of partners in five‑program pact – June 2–3, 2026 update

on

After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing

on

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

on

Sapu Nano showcases Deciparticle nanomedicine and AI‑driven oncology programs at BIO 2026

on

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

on

Regeneron Signs $2.3 Billion Pact with Parabilis for Novel ADC-Like Antibody–Helicon Conjugates

on